Dr Reddy’s Laboratories (RDY) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Dr. Reddy’s Laboratories has been named as a defendant in multiple lawsuits related to the Revlimid antitrust action in the United States. The company, along with other defendants, has filed motions to dismiss these lawsuits and plans to vigorously defend its position. The outcome of these legal challenges could impact Dr. Reddy’s stock performance and market perception.
For further insights into RDY stock, check out TipRanks’ Stock Analysis page.